In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO), with a price target of $13. The company’s shares closed yesterday at $4.49.
Selvaraju said:
“Our 12-month price target is derived from a market value of the firm at $1.3B, which includes a discounted cash flow based asset value for 15% discount rate, 2% terminal growth rate and 80% probability of success. Risks include, but are not limited to: (1) failure of VGX-3100 in clinical trials; (2) failure of VGX-3100 to secure regulatory approval; (3) failure of VGX-3100 to achieve commercial success due to market size, penetration rate, and/or competition; and (4) potential failures of other pipeline candidates.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -2.9% and a 36.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Inovio Pharmaceuticals is a Strong Buy with an average price target of $11, implying a 145.0% upside from current levels. In a report issued on August 8, Maxim Group also assigned a Buy rating to the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
Based on Inovio Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $6.64 million. In comparison, last year the company had a GAAP net loss of $9.48 million.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. Last month, Peter Kies, the CFO of INO sold 35,000 shares for a total of $155,250.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
